Delcath Systems
Pharmaceuticals, 1633 Broadway Ste 22C, New York, 10019, United States, 11-50 Employees
Phone Number: +19*********
Who is DELCATH SYSTEMS
Delcath Systems, Inc. (NASDAQ- DCTH) is a specialty pharmaceutical and medical device company focused on the treatment of primary and metastatic liver cancers. Our proprietary product---M...
Read More
-
Headquarters: 1633 Broadway Ste 22C, New York, New York, 10019, United States
-
Date Founded: 1987
-
Employees: 11-50
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
Industry: Pharmaceuticals
SIC Code: 3841
|
NAICS Code: 339112 |
Show More
Does something look wrong? Fix it. | View contact records from DELCATH SYSTEMS
Delcath Systems Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Delcath Systems
Answer: Delcath Systems's headquarters are located at 1633 Broadway Ste 22C, New York, 10019, United States
Answer: Delcath Systems's phone number is +19*********
Answer: Delcath Systems's official website is https://delcath.com
Answer: Delcath Systems's revenue is $1 Million to $5 Million
Answer: Delcath Systems's SIC: 3841
Answer: Delcath Systems's NAICS: 339112
Answer: Delcath Systems has 11-50 employees
Answer: Delcath Systems is in Pharmaceuticals
Answer: Delcath Systems contact info: Phone number: +19********* Website: https://delcath.com
Answer: Delcath Systems, Inc. (NASDAQ- DCTH) is a specialty pharmaceutical and medical device company focused on the treatment of primary and metastatic liver cancers. Our proprietary product---Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS)---is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure. Delcath is in late-stage clinical development in the United States with initial commercial activities in Europe, where the Melphalan/HDS is marketed as a CE Marked device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). Our commercial strategy for CHEMOSAT is to steadily grow clinical adoption in major European markets and utilize physician experience to support appeals for reimbursement. Since launch over 250 CHEMOSAT treatments have been performed at over 20 leading European cancer centers. In 2016, we launched our FOCUS Pivotal Study in Hepatic Dominant Ocular Melanoma, and are investigating orphan indications in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. We believe Melphalan/HDS is uniquely positioned to treat the entire liver as a stand-alone or complementary therapy.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month